Search

Your search keyword '"NPS Pharmaceuticals Inc."' showing total 1,682 results
Start Over Descriptor "NPS Pharmaceuticals Inc."
1,682 results on '"NPS Pharmaceuticals Inc."'

1. Biotechnology Industry Profile: Canada.

Subjects
BIOTECHNOLOGY industries, BIOTECHNOLOGY, TECHNOLOGY, INDUSTRIAL statistics, STATISTICS
Abstract

Presents a profile of the Biotechnology industry in Canada. Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry; Market forecasts; Demographics; Further reading.

Published
2005

2. Omega Therapeutics Expands Board of Directors with Appointment of Luke Beshar

Subjects
Cambrex Corp., Shire PLC, NPS Pharmaceuticals Inc., Corporate directors -- Appointments, resignations and dismissals, Specialty chemicals industry, Boards of directors -- Appointments, resignations and dismissals, Chief financial officers -- Appointments, resignations and dismissals, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Former Chief Financial Officer of NPS Pharmaceuticals and Cambrex Corporation CAMBRIDGE, Mass., June 23, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. ('Omega'), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming(TM) [...]

Published
2021

3. Full-length human recombinant parathyroid hormone for the treatment of osteoporosis.

Author

Cheng, Christine M. and El-Ibiary, Shareen Y.

Subjects
PARATHYROID hormone, OSTEOPOROSIS in women, THERAPEUTICS
Abstract

Full-length or intact parathyroid hormone [rDNA origini for injection (PTH [1–84], Preos, NPS Pharmaceuticals) is currently under FDA review for the treatment of postmenopausal osteoporosis. If approved, parathyroid hormone (1–84) will join teriparatide (PTH [1–34], Forteo, Lilly), the truncated N-terminal (1–34) form of the hormone, as the only anabolic therapies available for osteoporosis treatment. There are currently no published head-to-head trials comparing teriparatide and intact parathyroid hormone, though the effects of each on bone mineral density and fracture rate reduction appear comparable. The adverse effects of the 2 formulations are similar, including injection site reactions, headache, dizziness, nausea, and hypercalcemia. More studies are needed to determine when and if parathyroid hormone monotherapy should be used, whether and how it should be used in conjunction with antiresorptive therapies, and which patient populations would benefit most from parathyroid hormone treatment. [ABSTRACT FROM AUTHOR]

Published
2006

4. ALX 111: ALX1-11, Parathyroid Hormone (1-84) – NPS Allelix, PREOS™, PTH, Recombinant Human Parathyroid Hormone, rhPTH (1-84).

Author

Limited, Adis International

Subjects
*PARATHYROID hormone, *CALCIUM regulating hormones, *STEROID hormones, *OSTEOPOROSIS, *THERAPEUTICS
Abstract

ALX 111 [parathyroid hormone (1-84) – NPS Allelix, recombinant human parathyroid hormone, rhPTH (1-84), PREOS[sup ™]] is a full-length, recombinant human parathyroid hormone. It has potential as an anti-osteoporotic agent, due to its properties as a bone formation stimulant. It has been recommended that ALX 111 should be given for 1 to 2 years and may be given in combination with an antiresorptive agent, such as estrogen or a bisphosphonate. In December 1999, Allelix Biopharmaceuticals merged with NPS Pharmaceuticals. This combined company is operating as NPS Pharmaceuticals in the US and as NPS Allelix in Canada. The merger has enabled a phase III study of ALX 111 to begin in the US, Europe and South America. NPS harmaceuticals has signed an agreement with Bio-Imaging Technologies, which will provide all image handling and analysis for this trial. Until 1994, Allelix Biopharmaceuticals and Glaxo in Canada were involved in a joint venture to investigate the efficacy of ALX 111 in osteoporosis. Allelix was subsequently, until September 1998, collaborating with Astra of Sweden in developing ALX 111. Astra had acquired exclusive worldwide rights to ALX 111 and was responsible for development of the agent. However, Astra returned all rights to ALX 111 to Allelix as a result of its merger with Zeneca to form AstraZeneca. In December 1999, Allelix Biopharmaceuticals merged with NPS Pharmaceuticals. This combined company is operating as NPS Pharmaceuticals in the US and as NPS Allelix in Canada. The merger has enabled a phase III study of ALX 111 to begin in the US, Europe and South America. The phase III trial of ALX 111 for the treatment of osteoporosis has completed patient enrolment, and phase II trials have been completed in Canada and the Netherlands. The 18-month, phase III, multicentre, placebo-controlled trial (Treatment of Osteoporosis with Parathyroid Hormone; TOP) has been designed to assess the bone-building and fracture-reducing potential of the drug, and over 2600 postmenopausal women with osteoporosis who have not received previous drug therapy for osteoporosis have been enrolled. Treatment will be completed in September 2003, but more than 75% of patients enrolled in the TOP study have chosen to enrol in an Open Label Extension Study (OLES), which allows for a total treatment period of up to 24 months. NPS Pharmaceuticals has signed an agreement with Bio-Imaging Technologies, which will provide all image handling and analysis for this trial. In September 2002, NPS Pharmaceuticals announced that it has met its patient enrolment target (n > 150) for its POWER (PTH for Osteoporotic Women on Estrogen Replacement) study; a 24-month phase III trial initiated in Europe in November 2001. In this trial, women with osteoporosis receive SC injections of ALX 111 or placebo, in combination with their existing hormone replacement therapies, to test the bone building potential of the drug. In addition to the POWER study, a clinical trial sponsored by the National Institutes of Health (NIH) is being conducted to evaluate the potential of ALX 111 to build bone in combination with another osteoporosis medication. The ‘PaTH' study (PTH/alendronate) is designed to assess the effect of various combinations and sequential uses of ALX 111 and Merck's Fosamax[sup ®], a drug for slowing the loss of bone due to osteoporosis. The PaTH study, initiated in May 2000 and scheduled to conclude in September 2003, involved 238 patients with postmenopausal osteoporosis. It is thought that alendronic acid and ALX 111, when administered in combination, may act in an additive manner to treat osteoporosis because they act in different ways; alendronic acid acts to inhibit resorption and ALX 111 speeds up bone formation and resorption, with a net increase in formation. Results of this study are still being analysed but preliminary results appear to be positive. The effect of ALX 111 on bone cell cultures under conditions of microgravity was tested in orbit on the Space Shuttle Columbia, which was launched on 16 January 2003 but did not survive re-entry. This study was one in a series of studies known as ‘OSTEO II', and had been prepared by researchers from NPS Pharmaceuticals using Millenium Biologix's OSTEO[sup ™] Mini-Lab System. Under space flight conditions, astronauts experience a loss in bone density at a rate up to ten times faster than that of earth-bound patients with osteoporosis, and it was hoped that this study would indicate the mechanism of action of ALX 111 at cellular and genetic levels. The results of these studies were represented by the samples of human bone cells, which were lost during the re-entry tragedy. [ABSTRACT FROM AUTHOR]

Published
2003

5. Entera Bio Announces Management Changes

Subjects
NPS Pharmaceuticals Inc., Pharmaceutical industry
Abstract

ENPNewswire-August 11, 2020--Entera Bio Announces Management Changes (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 10082020 - BOSTON - Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered [...]

Published
2020

6. NPS Pharmaceuticals Reports 2nd Quarter 2012 Financial Results.

Subjects
FINANCIAL statements, BUSINESS revenue, BUSINESS losses, INVESTMENTS
Abstract

The article presents information about the financial statement of NPS Pharmaceuticals Inc. for the second quarter of 2012. It reported its net income of 7.4 million U.S. dollars for the second quarter of 2012 as compared to a net loss of 6.1 million U.S. dollars for the second quarter of 2011. Its cash and investments totaled to 110.4 million U.S. dollars.

Published
2012

7. New Findings from REPLACE Study Support Potential of Natpara(TM) to Treat Adult Hypoparathyroidism.

Subjects
CLINICAL drug trials, HYPOPARATHYROIDISM, POSTER presentations, DRUG efficacy, MEETINGS, THERAPEUTICS
Abstract

The article offers information on the findings of placebo controlled phase three Replace study which was conducted by NPS Pharmaceuticals Inc. to evaluate the efficacy of the drug, Natpara in treatment of hypoparathyroidism in adults. The results were discusses with the help of oral and poster presentations at recently held the ENDO 2012 annual meeting of the Endocrine Society in Houston, Texas.

Published
2012

8. Digestive Disease Week Presentations Support Therapeutic Potential for Gattex (teduglutide) as Novel Treatment for Adult Short Bowel Syndrome.

Subjects
MEETINGS, POSTER presentations, CLINICAL trials, DRUG efficacy, INTESTINAL disease treatment
Abstract

The article offers information on the results of clinical trials which was presented by NPS Pharmaceuticals Inc. at the Digestive Disease Week (DDW) meeting held in San Diego from May 19-22, 2012 to demonstrate the efficacy of the drug, Gattex in treatment of short bowel syndrome (SBS). The positive results related with the study were presented with the help of poster presentation.

Published
2012

9. NPS Pharmaceuticals Reports 1st Qtr 2012 Financial Results.

Subjects
FINANCIAL statements, QUARTERLY reports, CONFERENCE calls (Telephone), MEETINGS, PARATHYROID hormone
Abstract

The article informs that NPS Pharmaceuticals Inc. has released its financial results for the 1st quarter of 2012. It further informs that the company will be presenting on Natpara, a recombinant human parathyroid hormone, at the annual meeting of The Endocrine Society in June 2012. It mentions that the company will be hosting a conference call to discuss the financial results.

Published
2012

10. NPS Pharmaceuticals Observes Rare Disease Day 2012.

Subjects
TREATMENT of rare diseases, CORPORATE sponsorship
Abstract

The article informs that NPS Pharmaceuticals Inc. will join the National Organization for Rare Disorders (NORD) Inc. on February 29, 2012 to observe World Rare Disease Day. National Institutes of Health (NIH) reports that 7,000 rare diseases are affecting millions of Americans while Food and Drug approved treatments are available only for 200 such diseases. It mentions that World Rare Disease Day, launched in Europe, is sponsored by NORD in the U.S.

Published
2012

11. NPS Pharmaceuticals Reports 2011 Year-End Financial Results and 2012 Cash Burn Guidance.

Subjects
FINANCIAL statements, CORPORATION reports, QUARTERLY reports, NET losses, RESEARCH & development finance
Abstract

The article provides information on the financial results of NPS Pharmaceuticals Inc. for the fourth quarter and full year ended December 31, 2011. The company reported a net loss of 8.6 million U.S. dollars for the fourth quarter of 2011 and a net loss of 36.3 million dollars for the full year 2011. Research & Development (R&D) expenses were 21.6 million U.S. dollars for the fourth quarter of 2011 and R&D expenses were 73.8 million dollars for the full year of 2011.

Published
2012

12. NPS Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase 3 REPLACE Study of NPSP558 in Hypoparathyroidism.

Subjects
HYPOPARATHYROIDISM, DRUG approval, DRUG efficacy, THERAPEUTICS
Abstract

The article reports on the results of the pivotal Phase 3 REPLACE study of NPSP558 in hypoparathyroidism by NPS Pharmaceuticals Inc. It notes that NPSP558 is the company's bioengineered replica of human parathyroid hormone for the treatment of hypoparathyroidism. It adds that the REPLACE study has shown positive results, which expect to file for Food and Drug Administration (FDA) approval of the drug in 2012.

Published
2011

13. NPS Pharmaceuticals Reports 3rd Qtr 2011 Financial Results and Improves Cash Burn Guidance.

Subjects
FINANCIAL statements, NET losses, INVESTMENTS, LIQUID assets
Abstract

The article reports on the financial statements of Bedminster, New Jersey-based NPS Pharmaceuticals Inc. for the third quarter of 2011. It says that the company achieved a net loss of 12.3 million dollars or 0.14 dollar per diluted share. It notes the increase of NPS Pharmaceuticals' cash and investments from 133.8 million dollars on December 31, 2010 to 189.6 million dollars on September 30, 2011.

Published
2011

14. Phase 3 GATTEX (teduglutide) Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome.

Subjects
CLINICAL trials, PEPTIDES, SHORT bowel syndrome, PARENTERAL feeding, THERAPEUTICS
Abstract

The article reports on the result of an open-label study on the safety and durability of GATTEX (teduglutide) in treating short term bowel syndrome in adults. NPS Pharmaceutical Inc. announced that GATTEX was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome. The study found that 91% of subjects responded to 12 months of GATTEX treatment in the trial.

Published
2011

16. GATTEX(r) (teduglutide) Shown to Reduce Parenteral Support Volume in Patients with Adult Short Bowel Syndrome.

Subjects
CLINICAL drug trials, GASTROINTESTINAL disease treatment, PARENTERAL therapy, BODY weight, DRUG approval
Abstract

The article reports the result of the Phase 3 study by NPS Pharmaceuticals Inc. on the efficacy of its Gattex (r) (teduglutide) drug in treating short bowel syndrome (SBS) and intestinal failure. Presented at a conference in Chicago, Illinois, the result states that Gattex reduces parenteral support (PS) volume in patients by an average of 4.4 liter weekly and their mean body weight remained unchanged. The company is expecting to file for its approval at U.S. Food and Drug Administration (FDA).

Published
2011

17. NPS Pharmaceuticals Reports First Quarter 2011 Financial Results.

Subjects
FINANCIAL performance, GASTROINTESTINAL diseases, ENDOCRINE diseases, CHIEF executive officers, FINANCE
Abstract

The article presents the first quarter financial performance in 2011 of the NPS Pharmaceuticals Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders in Bedminster, New Jersey. It shows the company's 9.2 million dollar net loss in the first quarter. However, chief executive officer (CEO) Francois Nader states that the success of its equity offering gives them the financial flexibility to deliver number of key milestones.

Published
2011

18. NPS Pharmaceuticals Supports Rare Disease Day.

Subjects
PHARMACEUTICAL industry, GASTROINTESTINAL disease treatment, ENDOCRINE diseases, SPECIAL days, RARE diseases, HYPOPARATHYROIDISM, THERAPEUTICS
Abstract

The article reports that NPS Pharmaceuticals Inc., a specialty pharmaceutical company that develops innovative treatments for rare gastrointestinal and endocrine disorders, will join the National Organization for Rare Disorders Inc. (NORD) for the World Disease Day on February 28, 2011. It says that NPS supports the Rare Disease Day to raise attention to rare diseases as an important public health concern worldwide. It adds that NPS focuses on short bowel syndrome (SBS) and hypoparathyroidism.

Published
2011

19. 8-K: Moderna, Inc

Subjects
NPS Pharmaceuticals Inc., Cybernet Data Systems Inc., Information technology services industry, Pharmaceutical industry, Computer services industry, Business, general
Abstract

(EDGAR Online via COMTEX) -- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of [...]

Published
2019

20. Cinacalcet: AMG 073, Calcimimetics – Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.

Author

Limited, Adis International

Subjects
*PARATHYROID glands, *HYPERPARATHYROIDISM, *PARATHYROID gland diseases, *ENDOCRINE diseases, *CALCIUM regulating hormones, *BONE metabolism endocrinology
Abstract

Cinacalcet [AMG 073, KRN 1493, NPS 1493] is an orally active, second-generation calcimimetic compound licensed by NPS Pharmaceuticals to Amgen in the US for potential treatment of hyperparathyroidism (HPT). Cinacalcet modulates (increases the sensitivity of) calcium receptors on the surface of parathyroid cells thereby inhibiting the oversecretion of parathyroid hormone, which characterises HPT. It also represents a potentially significant advance for chronic kidney disease patients diagnosed with secondary HPT, a common yet serious metabolic disorder where parathyroid hormone levels are elevated. Patients with this disease can suffer from bone disease, bone pain and fractures, soft tissue calcification, vascular calcification and cardiovascular complications. Amgen has rights to develop and sell cinacalcet throughout the world except in Japan, Taiwan and China, where the compound was licensed to Kirin Brewery. Kirin is developing it as KRN 1493 in phase II clinical studies in Japan. In December 2001, commencement of a phase III clinical trial with cinacalcet for the treatment of secondary HPT, triggered a $US3 million milestone payment to NPS Pharmaceuticals. In September 2003, submission of an NDA to the US FDA for cinacalcet for secondary HPT will be followed by a milestone payment of $US6 million to NPS. NPS, Kirin and Amgen were also developing another compound, tecalcet, for HPT, but that project has been discontinued in favour of cinacalcet. In September 2003, Amgen submitted an NDA to the US FDA for secondary HPT in patients with chronic kidney disease. In April 2003, Amgen announced positive results from a phase III clinical trial with cinacalcet in patients with secondary HPT. In a clinical study in patients on dialysis suffering from the effects of chronically elevated levels parathyroid hormone, cinacalcet appeared to be safe and well tolerated and was significantly more effective than placebo. Two more additional efficacy studies with cinacalcet have also been completed. Phase II trials of cinacalcet in dialysis patients with secondary HPT and in patients with primary HPT were successfully completed. [ABSTRACT FROM AUTHOR]

Published
2003

21. Cinacalcet.

Subjects
*DRUG development, *HYPERPARATHYROIDISM treatment
Abstract

Focuses on the orally active, second generation calcimimetic compound Cinacalcet licensed by NPS Pharmaceuticals to Amgen in the U.S. for the potential treatment of hyperparathyroidism. Features and properties; Information on the therapeutic trials; Drug development history.

Published
2003
Full Text
View/download PDF

22. Shire UK

Subjects
United States. Food and Drug Administration, Dyax Corp., Baxalta Inc., Shire PLC, NPS Pharmaceuticals Inc., Biotechnology industries, Pharmaceutical industry, Business, international, Firazyr (Medication), Cinryze (Medication)
Abstract

About Us Shire traces its history back to 1986, when a small team of entrepreneurs sought out a solution to address on a number of unmet medical needs. Within its [...]

Published
2016

23. Shire UK

Subjects
United States. Food and Drug Administration, Dyax Corp., Baxalta Inc., Shire PLC, NPS Pharmaceuticals Inc., Biotechnology industries, Pharmaceutical industry, Business, international, Firazyr (Medication), Cinryze (Medication)
Abstract

About Us Shire traces its history back to 1986, when a small team of entrepreneurs sought out a solution to address on a number of unmet medical needs. Within its [...]

Published
2016

24. Roche Products UK

Subjects
United States. Food and Drug Administration, Dyax Corp., Baxalta Inc., Shire PLC, NPS Pharmaceuticals Inc., Health care industry, Biotechnology industries, Medical personnel, Cardiac patients, Pharmaceutical industry, Health care industry, Business, international, Firazyr (Medication), Cinryze (Medication)
Abstract

About Us At Roche our aim is to improve the health, quality of life and well-being of people around the world by providing an innovative range of diagnostic solutions and [...]

Published
2016

25. Roche Products UK

Subjects
United States. Food and Drug Administration, Dyax Corp., Baxalta Inc., Shire PLC, NPS Pharmaceuticals Inc., Health care industry, Biotechnology industries, Medical personnel, Cardiac patients, Pharmaceutical industry, Health care industry, Business, international, Firazyr (Medication), Cinryze (Medication)
Abstract

About Us At Roche our aim is to improve the health, quality of life and well-being of people around the world by providing an innovative range of diagnostic solutions and [...]

Published
2016

26. Shire UK

Subjects
United States. Food and Drug Administration, Dyax Corp., Baxalta Inc., Shire PLC, NPS Pharmaceuticals Inc., Biotechnology industries, Pharmaceutical industry, Business, international, Firazyr (Medication), Cinryze (Medication)
Abstract

About Us Shire traces its history back to 1986, when a small team of entrepreneurs sought out a solution to address on a number of unmet medical needs. Within its [...]

Published
2016

27. Roche Products UK

Subjects
United States. Food and Drug Administration, Dyax Corp., Baxalta Inc., Shire PLC, NPS Pharmaceuticals Inc., Health care industry, Biotechnology industries, Medical personnel, Cardiac patients, Pharmaceutical industry, Health care industry, Business, international, Firazyr (Medication), Cinryze (Medication)
Abstract

About Us At Roche our aim is to improve the health, quality of life and well-being of people around the world by providing an innovative range of diagnostic solutions and [...]

Published
2016

28. NPS Pharmaceuticals Announces Extension of Action Date for Gattex(r) NDA to Dec 30 2012.

Subjects
THERAPEUTICS, DRUG approval, GLUCAGON-like peptides, PHARMACEUTICAL research
Abstract

The article informs that the pharmaceutical firm developing therapeutics for rare gastrointestinal and endocrine disorders NPS Pharmaceuticals Inc. has received a communication from the U.S. Food & Drug Administration (FDA) extending the Prescription Drug User Fee Act (PDUFA) action date for its new drug application(NDA) for the product "Gattex," a teduglutide. It informs that Gattex is recombinant analog of human glucagon-like peptide 2.

Published
2012

29. NPS Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Gattex(r) (teduglutide).

Subjects
DRUG approval, GASTROINTESTINAL agents, MEETINGS, SHORT bowel syndrome, THERAPEUTICS
Abstract

The article presents information on an announcement made by NPS Pharmaceuticals Inc. regarding the notice from the U.S. Food & Drug Administration (FDA) to discuss its New Drug Application (NDA) for the approval of drug Gattex at the Gastrointestinal Drugs Advisory Committee meeting to be held on October 16, 2012. The proposed idea for Gattex is the treatment of patients with short bowel syndrome.

Published
2012

30. NPS Pharmaceuticals Joins the Oley Foundation in Recognizing HPN Awareness Week, Aug 5-11.

Subjects
PARENTERAL feeding, NUTRIENT uptake, DIET, LOCAL mass media, BLOGS
Abstract

The article provides information on the Oley Foundation's second annual Home Parenteral Nutrition (HPN) Awareness Week being held from August 5-11, 2012 supported by NPS Pharmaceuticals Inc. It informs HPN is an intravenous fluid for patients who are unable to receive enough nutrients from a normal diet. It further informs that HPN patients are encouraged to share their stories with local media, upload videos on YOUTUBE or blog about their experiences.

Published
2012

31. NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to be Presented at ENDO, the annual meeting of The Endocrine Society.

Subjects
MEETINGS, ENDOCRINE glands, CONFERENCES & conventions
Abstract

The article offers information on ENDO 2012, the annual meeting of The Endocrine Society to be held in Houston, Texas on June 23-26, 2012 where NPS Pharmaceuticals Inc. will be presenting three abstracts with respect to the phase III REPLACE study of its product Natpara in hypoparathyroidism.

Published
2012

32. NPS Pharmaceuticals Reports Four Additional Patients Achieve Independence from Parenteral Support in STEPS 2 Study of Gattex(r) in Adult Short Bowel Syndrome.

Subjects
PHARMACEUTICAL industry, GASTROINTESTINAL diseases, ENDOCRINE diseases, PARENTERAL feeding, INTRAVENOUS fat emulsions, SHORT bowel syndrome
Abstract

The article presents information on an announcement made by the pharmaceutical company NPS Pharmaceuticals Inc. focusing on treatment for gastrointestinal and endocrine disorders, on the success in the use of Gattex therapy that use teduglutide. The treatment can be used in the case of parenteral nutrition and intravenous fluids in short bowel syndrome of adults.

Published
2012

34. NPS Pharmaceuticals Submits Chemistry, Manufacturing and Controls (CMC) Section of New Drug Application for GATTEX(r).

Subjects
DRUG development, SHORT bowel syndrome, DRUG utilization, THERAPEUTICS
Abstract

The article reports on the submission by NPS Pharmaceuticals, Inc. of the chemistry, manufacturing and controls (CMC) portion of its new drug application (NDA) for GATTEX(r) to the U.S. Food and Drug Administration (FDA). It states that the company develops GATTEX(r) to treat adults with short bowel syndrome (SBS). NPS Pharmaceuticals president Francois Nader comments on the submission.

Published
2011

35. NPS Pharmaceuticals Completes Patient Randomization in Phase 3 REPLACE Study of NPSP558 in Hypoparathyroidism.

Subjects
CLINICAL trials, PARATHYROID hormone, BIOMEDICAL engineering, PLACEBOS, HYPOPARATHYROIDISM, HORMONE therapy, CALCIUM, THERAPEUTICS
Abstract

The article focuses on the completion of the Phase 3 REPLACE study of NPS Pharmaceuticals Inc. for its NPSP558, a bioengineered form of human parathyroid hormone 1-84. REPLACE was a double-blind placebo-controlled study, which assesses the use of NPSP558 as hormone replacement therapy in adult patients with hypoparathyroidism. Moreover, results from an investigator-initiated Phase 2 study showed that NPSP558 treatment reduces supplemental calcium and 1,25-dihydroxyvitamin D requirements.

Published
2011

36. CFO OF THE YEAR.

Subjects
CHIEF financial officers, PUBLIC companies, AWARDS
Abstract

The article features NPS Pharmaceuticals senior vice president and chief financial officer (CFO) Luke M. Beshar, winner of the NBIZ CFO of the Year in the public company category in 2010. He had his job in public accounting after graduating with a bachelor's degree but found that this was too retrospective for his taste so he decided to take a CFO position. Information on the growth of NPS when he joined the firm is provided. Other finalists for the award include Silvano Dall'Asta of Siemens Corporate Research and David Lamadrid of CytoSorbents.

Published
2010

37. NPS: Ripe for a Buyout.

Author

Marcial, Gene G.

Subjects
FINANCIAL performance, INVESTMENT analysis, DRUG development, RECOMBINANT proteins, MERGERS & acquisitions, BUSINESS forecasting
Abstract

Focuses on the financial performance of NPS Pharmaceuticals, a developer of recombinant proteins to treat various disorders. View of John McCamant that a large drugmaker might buy NPS and that the shares are undervalued; Projects that NPS is working on with Amgen, AstraZeneca, and GlaxoSmithKline; Government approval for Sensipar, which will be marketed by Amgen; Outlook for the drug Preos; View of Merrill Lynch's Eric Ende that NPS is a takeover target.

Published
2004

38. Revestive Gets European Marketing Authorization for the Treatment of Adults with SBS

Subjects
NPS Pharmaceuticals Inc., Adults, Pharmaceutical industry, Arts and entertainment industries, European Union. European Commission
Abstract

Takeda Pharmaceutical Company and NPS Pharmaceuticals, Inc. jointly announced that the European Commission (EC) has granted European market authorization for the medicinal product teduglutide (trade name in Europe: Revestive) as [...]

Published
2012

39. Shire files for FDA approval of a new plasma manufacturing facility in Covington Georgia to support growing Immunology franchise

Subjects
United States. Food and Drug Administration, Shire PLC, NPS Pharmaceuticals Inc., Pharmaceutical industry, Gammagard (Medication)
Abstract

ENPNewswire-December 29, 2017--Shire files for FDA approval of a new plasma manufacturing facility in Covington Georgia to support growing Immunology franchise (C)2017 ENPublishing - http://www.enpublishing.co.uk Release date- 28122017 - Dublin, [...]

Published
2017

40. Profile of Francois Nader Non-Executive Director of Advanced Accelerator Applications

Subjects
NPS Pharmaceuticals Inc., Chief operating officers, Corporate directors, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

New York: Following is the Profile of Francois Nader Non-Executive Director of Advanced Accelerator Applications: Francois Nader became a member of our board of directors in May 2016. Francois Nader, [...]

Published
2017

41. BioUtah Announces 2017 Utah Life Sciences Awards at Annual Life Sciences Summit

Subjects
NPS Pharmaceuticals Inc., Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

SALT LAKE CITY: BioUtah has issued the following news release: BioUtah, Utah's independent, non-profit trade association dedicated solely to the life sciences community, today announced its 2017 Life Sciences award [...]

Published
2017

42. CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients' Previous Immunoglobulin Therapy

Subjects
Baxalta Inc., Shire PLC, NPS Pharmaceuticals Inc., Biotechnology industries, Pharmaceutical industry
Abstract

ENPNewswire-March 7, 2017--CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients' Previous Immunoglobulin Therapy (C)2017 ENPublishing - http://www.enpublishing.co.uk Release date- 06032017 - Lexington, Mass. [...]

Published
2017

43. CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients' Previous Immunoglobulin Therapy

Subjects
Baxalta Inc., Shire PLC, NPS Pharmaceuticals Inc., Immunodeficiency -- Care and treatment, Patient satisfaction, Biotechnology industries, Medical research, Pharmaceutical industry, Immunoglobulins, Business, News, opinion and commentary
Abstract

Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients LEXINGTON, Massachusetts, March 6, 2017 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: [...]

Published
2017

44. NPS Pharmaceuticals Announces Hypoparathyroidism Data to be Presented at Annual Meeting of American Society for Bone and Mineral Research

Subjects
NPS Pharmaceuticals Inc., Parathyroid hormone, Hormone therapy, Pharmaceutical industry, Hypoparathyroidism, Health, American Society for Bone and Mineral Research
Abstract

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced that data about hypoparathyroidism will be presented at the 2011 Annual [...]

Published
2011

45. Event Brief of NPS Pharmaceuticals Inc Conference Call to discuss FDA Advisory Committee to Review Natpara[R] Biologics License Application - Final

Subjects
NPS Pharmaceuticals Inc., Financial markets, Drug approval, Pharmaceutical industry, Business
Abstract

CORPORATE PARTICIPANTS . Susan Mesco - NPS Pharmaceuticals, Inc.,Executive Director, IR . Francois Nader - NPS Pharmaceuticals, Inc.,President and CEO . Roger Garceau - NPS Pharmaceuticals, Inc.,Chief Medical Officer CONFERENCE [...]

Published
2014

46. Pharma company expands scope of new drug application PREOS

Subjects
NPS Pharmaceuticals Inc., Pharmaceutical industry, Health, Obesity
Abstract

2005 JAN 1 - (NewsRx.com & NewsRx.net) -- NPS Pharmaceuticals, Inc., (NASDAQ:NPSP) announced that the company will expand the scope of the New Drug Application (NDA) it is preparing for [...]

Published
2005

47. Pharma company expands scope of new drug application PREOS

Subjects
NPS Pharmaceuticals Inc., Women -- Health aspects, Pharmaceutical industry
Abstract

2004 DEC 30 - (NewsRx.com & NewsRx.net) -- NPS Pharmaceuticals, Inc., (NASDAQ:NPSP) announced that the company will expand the scope of the New Drug Application (NDA) it is preparing for [...]

Published
2004

48. Promotion agreement announced for Kineret rheumatoid arthritis therapy

Subjects
NPS Pharmaceuticals Inc., Amgen Inc., Pharmaceutical industry, Health, Obesity, Rheumatology
Abstract

2004 SEP 11 - (NewsRx.com & NewsRx.net) -- NPS Pharmaceuticals, Inc., (NPSP) has executed an agreement with Amgen Inc. to promote Kineret, a biologic therapy for the treatment of moderate [...]

Published
2004

50. Pharmaceutical companies announce $90M marketing agreement for Europe

Subjects
NPS Pharmaceuticals Inc., Health, Obesity, Pharmaceutical industry
Abstract

2004 JUN 5 - (NewsRx.com & NewsRx.net) -- NPS Pharmaceuticals, Inc., (NPSP) and Nycomed Group announced that they have signed a distribution and license agreement granting Nycomed rights to develop [...]

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results